Newamsterdam Pharma Presents Addl Data From BROADWAY And TANDEM Pivotal Phase 3 Studies As Late-breaking Oral Presentations At EAS 2025 And Publishes In Leading Medical Journals

Author: Benzinga Newsdesk | May 07, 2025 07:20am

– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) –

– Phase 3 data showed that obicetrapib as an adjunct to statins, whether in combination with ezetimibe or as monotherapy, reduced LDL-C by 50% and 35%, respectively; in addition, Phase 2 data of obicetrapib in combination with moderate-dose statins showed LDL-C reductions of approximately 70% –

– 21% observed reduction in major adverse cardiovascular events (HR=0.79, CI 0.54-1.15) in BROADWAY trial –

– Pooled Phase 3 data showed Lp(a) reductions of 45% across BROADWAY, TANDEM, and BROOKLYN trials for patients with increased risk levels of Lp(a) from 50-150 nmol/L at baseline –

NAARDEN, The Netherlands and MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS, " "we, " or the "Company"))), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced additional data from the BROADWAY and TANDEM pivotal Phase 3 studies were presented as late-breaking oral presentations at the European Atherosclerosis Society Congress ("EAS") 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM).

Posted In: NAMS